ESTRO meets Asia 2024 - Abstract Book

S65

Interdisciplinary – Brachytherapy

ESTRO meets Asia 2024

Purpose/Objective:

Short-course external beam radiotherapy (EBRT) and intraluminal brachytherapy are both accepted treatments for the palliation of dysphagia in patients with incurable oesophageal cancer. We compared the effects of a combinations of EBRT and Brachytherapy with a current standard regimen of EBRT.

To compare dysphagia relief (change in grade of dysphagia) in radiation naïve oesophageal cancer patients with high-grade dysphagia.

Material/Methods:

We performed a prospective study of patients with metastasized or otherwise incurable oesophageal cancer requiring palliation of dysphagia from May 2023 to March 2024. Patients were treated with EBRT in ten fractions of 3 Gy each (total dose 30 Gy). Data was compared with patients treated with EBRT 12 Gy /3 fractions followed by intraluminal brachytherapy dose of 6 Gy x 2 fractions.

Results:

Between May 2023 to February 2024, a total of 18 patients were studied of whom 8 were taken in EBRT arm and 10 in ILRT arm. Pre-treatment median dysphagia score for EBRT arm was 3.5 and ILRT arm 3 [ p < 0.32]. At 1 month post treatment, median dysphagia score for EBRT arm was 2.5 and ILRT arm 1.5 [ p< 0.01].

Conclusion:

EBRT followed by ILRT is seen to be more effective in dysphagia relief compared to EBRT only arm. The studied cases are still under follow up for reviewing change if any in dysphagia patterns at longer follow ups.

Keywords: Esophagus, Dysphagia, Brachytherapy

References:

1. Zhang Y. Epidemiology of esophageal cancer. World J Gastroenterol. 2013; 19:5598–5606.

2. Sur RK, Donde B, Levin CV, et al. Fractionated high dose rate intraluminal brachytherapy in palliation of advanced oesophageal cancer.1998;40:447-453

3. Steyerberg EW, Homs MY, Stokvis A, et al. SIREC Study Group. Stent placement or brachytherapy for palliation of dysphagia from esophageal cancer: a prognostic model to selection guide treatment

4. Kulhavy M, Levin CV, Sur RK. Optimization of single fraction high dose rate intraluminal brachytherapy in palliation of advanced esophageal cancer 1999;11:235-239

5. Lettmaier S, Strnad V. Intraluminal brachytherapy in oesophageal cancer: defining its role and introducing the technique.

6. Homs MY, Steyerberg EW, Eijkenboom WM, et al. Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: a multicentre randomized trial. Lancet. 2004;364:1497–1504